Pfizer and BioNTech To Supply Qatar With Their bnt162 Mrna-Based Vaccine Candidate Against Sars-Cov-2

Pfizer Inc. and BioNTech SE today announced an agreement with the Ministry of Public Health in Qatar to supply their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval, by the end of 2020 to 2021.

Financial details of the agreement were not disclosed. As requested by the Vaccine Procurement Taskforce Team, on behalf the Government of Qatar, deliveries are planned for the end of 2020 to 2021, subject to clinical success and local regulatory approval.

“We are deeply honored to work with the Qatar government and to marshal our scientific and manufacturing resources toward our shared goal of bringing a potential COVID-19 vaccine to the Qatar people as quickly as possible,” said Lindsey Dietschi, Pfizer Gulf Cluster Lead. “In the face of this global health crisis, Pfizer’s purpose – breakthroughs that change patients’ lives – has taken on an even greater urgency. Our hope is that, subject to clinical and regulatory success, our vaccine will help make this happen.”

“I would like to thank the Qatar government for its support and putting trust in our ability to develop a vaccine that, we believe, has the potential to help address this global pandemic threat. Our goal remains to create a global supply of a safe and effective COVID-19 vaccine for many people around the world, as quickly as we can,” said Sean Marett, Chief Business and Chief Commercial Officer at BioNTech.

Dr. Aisha Ibrahim AlAnsari, the Chair of the Vaccine Procurement Taskforce commented: “The State of Qatar has spared no effort in ensuring a rapid and timely response in this fight against the novel coronavirus COVID-19. Our citizens and residents are our utmost priority and we are taking all the necessary steps to ensure the timely availability of a safe and effective vaccine against Covid-19. With this partnership, we continue our efforts to combat the virus.”

In addition to engagements with governments, Pfizer and BioNTech have provided an expression of interest for possible supply to the COVAX Facility, a mechanism established by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and World Health Organization (WHO) that aims to provide governments, including those in the emerging markets, with early access to a large portfolio of COVID-19 candidate vaccines using a range of technology platforms, produced by multiple manufacturers across the world.